The objective of this national, prospective, multi-centre observational study is to describe the
prescription rational and practice in Germany, confirm the efficacy of caplacizumab in a realworld
setting, and identify predicting factors in iTTP-patients with regard to persistent
autoimmune activity, therapy guidance and risk of complications. The rational is to develop
new treatment algorithms that optimize overall patient outcome and reduce treatment cost.